drugset / Trial / NCT05983874
A Study to Evaluate the Safety and Immunogenicity of 2 Doses of 100µg BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, Given to a Population of Adults Who Have Received 3 Doses of 300µg BG505 SOSIP.GT1.1 gp140 Vaccine, Adjuvanted
Phase 1
Unknown
8 enrolled
International AIDS Vaccine Initiative
3M · collabAccess to Advanced Health Institute (AAHI) · collabPolymun Scientific GmbH · collab
NaSingle-groupOpen-labelPrevention
Summary
An Open-Label Study to Evaluate the Safety and Immunogenicity of 2 Doses of 100µg BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, given to a Population of Adults in Good General Health Who have Received 3 doses of 300µg BG505 SOSIP.GT1.1 gp140 Vaccine, Adjuvanted
Timeline
- Start
- 2024-04-16
- Primary completion
- 2025-03
- Completion
- 2025-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BG505 SOSIP.664 gp140 | Vaccine | 100 ug | Intramuscular |
| Background | 3M-052-AF | Small molecule | — | Intramuscular |
| Background | Aluminum hydroxide | Unknown | — | Intramuscular |